Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986938 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL28666005 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL18986940 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL20554188 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL4525698 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL28375692 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL23906106 | 0.90 | NR1H2 (0.64) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL21561564 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27440647 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL17630406 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4727543-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727542-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| EP-3390402-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815876-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | NR1H4, FXR1, GPBAR1 | NR1H2 6/4885CHRM2 1681/4885CHRM1 1576/4885 |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | NR1H2 68/4885CHRM2 1340/4885CHRM1 1748/4885 |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GLP1R | NR1H2 158/4885CHRM2 1791/4885CHRM1 1616/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | NR1H2 308/4885CHRM2 172/4885CHRM1 143/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | NR1H2 400/4885CHRM2 4760/4885CHRM1 4074/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | NR1H2 125/4885CHRM2 2244/4885CHRM1 2211/4885 |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | NR1H2 869/4885CHRM2 4756/4885CHRM1 4827/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | NR1H2 3712/4885CHRM2 409/4885CHRM1 376/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | NR1H2 450/4885CHRM2 185/4885CHRM1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.